| Trial ID: | L5419 |
| Source ID: | NCT03254849
|
| Associated Drug: |
Empagliflozin
|
| Title: |
Empagliflozin and Sympathetic Nerve Traffic
|
| Acronym: |
|
| Status: |
COMPLETED
|
| Study Results: |
NO
|
| Results: |
|
| Conditions: |
Type 2 Diabetes Mellitus
|
| Interventions: |
DRUG: Empagliflozin|DRUG: Hydrochlorothiazide 25 mg
|
| Outcome Measures: |
Primary: Blood Pressure reduction, Blood pressure reduction with empagliflozin treatment is associated with lesser increase in sympathetic nerve traffic when compared to Hydrochlorothiazide treatment, 6 weeks |
|
| Sponsor/Collaborators: |
Sponsor: Profil Institut für Stoffwechselforschung GmbH
|
| Gender: |
ALL
|
| Age: |
ADULT, OLDER_ADULT
|
| Phases: |
PHASE4
|
| Enrollment: |
75
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT
|
| Start Date: |
2017-12-08
|
| Completion Date: |
2020-04-20
|
| Results First Posted: |
|
| Last Update Posted: |
2020-07-14
|
| Locations: |
Profil Institut für Stoffwechselforschung GmbH, Neuss, North Rhine-Westphalia, 41460, Germany
|
| URL: |
https://clinicaltrials.gov/show/NCT03254849
|
